Found 1816 clinical trials
PAXG Out in the Country
The objective of this study is to assess the reproducibility of PAXG regimen as first-line/primary chemotherapy in daily clinical practice in Pancreatic Ductal Adenocarcinoma (PDAC) borderline resectable, locally advanced or metastatic patients out of a large volume center.
- 0 views
- 05 Aug, 2020
Neoadjuvant RCT Versus CT for Patients With Locally Advanced Potentially Resectable Adenocarcinoma of the GEJ
This is a multicenter, prospective, randomized, stratified, controlled, open-label study comparing neoadjuvant radiochemotherapy with FLOT versus FLOT chemotherapy alone fr patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction (GEJ)
- 0 views
- 05 Aug, 2020
Surgery Plus Chemo Versus Chemoradiotherapy Followed by Surgery Plus Chemo for Locally Recurrent Rectal Cancer
JCOG1801 is a randomized phase III trial which was initiated in Japan in August 2019 to confirm the superiority of preoperative chemoradiotherapy followed by surgery plus adjuvant chemotherapy for local relapse-free survival over standard treatment, i.e. surgery plus adjuvant chemotherapy, for previously non-irradiated locally recurrent rectal cancer.
- 0 views
- 16 Feb, 2024
- 45 locations
Safety Pharmacokinetics and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation
Primary Objectives: Phase 1: To characterize the safety and tolerability of isatuximab in kidney transplant candidates. Phase 2: To evaluate the efficacy of isatuximab in desensitization of patients awaiting kidney transplantation. Secondary Objectives: Phase 2: To characterize the safety profile of isatuximab in kidney transplant candidates. To characterize the pharmacokinetic …
- 0 views
- 16 Feb, 2024
- 2 locations
GPED Regimen for Relapsed/Refractory or Advanced ENKTCL
The purpose of this study is to evaluate the efficacy and safety of gemcitabine, pegaspargase, etoposide, and dexamethasone (GPED) in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma patients (ENKTCL).
- 0 views
- 16 Feb, 2024
- 1 location
A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) and maximum tolerated dose (MTD) of JNJ-70218902 in Part 1, and to determine the safety of JNJ-70218902 RP2D(s) in Part 2.
- 0 views
- 16 Feb, 2024
- 7 locations
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor Copanlisib Given in Combination With the Immunotherapeutic Agents Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
Patients with relapsed or refractory follicular or marginal zone lymphoma who have received at least one prior line of therapy will receive Copanlisib IV: day 1, 8, 15 every 28 days Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only Rituximab IV: Cycle 1 days 1, 8, …
- 0 views
- 16 Feb, 2024
- 1 location
Improving Uptake of Genetic Cancer Risk Assessment in African American Women- Video
Genetic counseling and testing (GCT) provides invaluable information for women who are at-risk of hereditary breast and/or ovarian cancer (HBOC). Black women underutilize GCT compared to White women. This study will conduct a RCT to test the efficacy of a culturally-tailored theory-based video intervention aimed to address key psychosocial factors …
- 0 views
- 16 Feb, 2024
- 1 location
Efficacy and Safety of Polyoxidonium in Hospitalized Patients With Coronavirus Disease COVID-19
The purpose of this study is to demonstrate the superiority of Polyoxidonium, lyophilizate for solution for injections and topical application, 6 mg over placebo in hospitalized patients with coronavirus disease (COVID-19). This is a multicentre prospective, randomized, double-blind, placebo-controlled, parallel-group phase IIb\IIIa clinical trial.
- 0 views
- 16 Feb, 2024
- 12 locations
Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers
This is a Phase 1, single-dose, open-label, randomized, three-period, three-way crossover study in which healthy adult participants will receive three separate single-dose administrations of ASTX660 capsules under three different conditions.
- 0 views
- 16 Feb, 2024
- 1 location